Funding
Strategic · Biotech

Beactica Therapeutics announces €2.5M strategic financing

Beactica Therapeutics announced €2.5 million in strategic financing in February, with the European Innovation Council named as a backer.

Updated Oct 16, 2026By RoundOS Funding desk

The company develops precision immune therapies for glioblastoma.

Funding history

Strategic · This round€2.5M

Sources

  1. Beactica Therapeutics ABprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related